NCT00635791View on ClinicalTrials.gov

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

March 31, 2012

Conditions
Malignant Solid TumourRenal Cell CarcinomaNon Small Cell Lung Carcinoma
Interventions
DRUG

Sorafenib

Given by mouth

DRUG

Vorinostat

Given by mouth

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | Biotech Hunter | Biotech Hunter